The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now
Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.
You may also be interested in...
Guardrails protecting the public from artificial intelligence and machine learning systems are under development in the US and internationally. Whether they will inhibit global pharmaceutical manufacturers remains an open question that is sure to be discussed in the months and years ahead.
There are so many ways to use artificial intelligence to boost the quality of drug products, but which ones are overblown, misconstrued or inappropriate for the problem you are trying to solve? Here’s how some experts are working through these challenges.
Explaining The Unexplainable: How To Win US FDA’s Trust In Artificially Intelligent Drug Manufacturing
One issue that has surfaced as the pharmaceutical industry responds to the US FDA’s recent discussion paper on manufacturing with AI machine learning models is the question of how to explain what the models are doing.